JP2024515826A - 眼疾患の処置のための薬学的組成物および硝子体内薬物送達システム - Google Patents

眼疾患の処置のための薬学的組成物および硝子体内薬物送達システム Download PDF

Info

Publication number
JP2024515826A
JP2024515826A JP2023566511A JP2023566511A JP2024515826A JP 2024515826 A JP2024515826 A JP 2024515826A JP 2023566511 A JP2023566511 A JP 2023566511A JP 2023566511 A JP2023566511 A JP 2023566511A JP 2024515826 A JP2024515826 A JP 2024515826A
Authority
JP
Japan
Prior art keywords
biodegradable
months
compound
ocular implant
biodegradable polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023566511A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024515826A5 (cg-RX-API-DMAC7.html
Inventor
チェン-ウェン リン,
アンジェラ ドーン グレンデニング,
セヴギ ギュルカン,
Original Assignee
パフューズ セラピューティクス, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by パフューズ セラピューティクス, インコーポレイテッド filed Critical パフューズ セラピューティクス, インコーポレイテッド
Publication of JP2024515826A publication Critical patent/JP2024515826A/ja
Publication of JP2024515826A5 publication Critical patent/JP2024515826A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023566511A 2021-04-30 2022-04-29 眼疾患の処置のための薬学的組成物および硝子体内薬物送達システム Pending JP2024515826A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163182559P 2021-04-30 2021-04-30
US63/182,559 2021-04-30
US202163287737P 2021-12-09 2021-12-09
US63/287,737 2021-12-09
PCT/US2022/027048 WO2022232588A1 (en) 2021-04-30 2022-04-29 Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases

Publications (2)

Publication Number Publication Date
JP2024515826A true JP2024515826A (ja) 2024-04-10
JP2024515826A5 JP2024515826A5 (cg-RX-API-DMAC7.html) 2025-05-20

Family

ID=83848732

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023566511A Pending JP2024515826A (ja) 2021-04-30 2022-04-29 眼疾患の処置のための薬学的組成物および硝子体内薬物送達システム

Country Status (10)

Country Link
US (3) US11786510B2 (cg-RX-API-DMAC7.html)
EP (1) EP4329753A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024515826A (cg-RX-API-DMAC7.html)
KR (1) KR20240004643A (cg-RX-API-DMAC7.html)
AU (1) AU2022264036A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023022705A2 (cg-RX-API-DMAC7.html)
CA (1) CA3218251A1 (cg-RX-API-DMAC7.html)
IL (1) IL307997A (cg-RX-API-DMAC7.html)
MX (1) MX2023012723A (cg-RX-API-DMAC7.html)
WO (1) WO2022232588A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7664239B2 (ja) 2019-10-30 2025-04-17 パフューズ セラピューティクス, インコーポレイテッド エンドセリンレセプターアンタゴニストを使用する眼疾患の処置
BR112023022705A2 (pt) * 2021-04-30 2024-01-16 Perfuse Therapeutics Inc Composições farmacêuticas e sistemas de entrega intravítrea de fármacos para o tratamento de doenças oculares
CN117295520A (zh) * 2021-04-30 2023-12-26 珀弗斯治疗股份有限公司 使用内皮素受体拮抗剂治疗眼部疾病
WO2025137005A1 (en) * 2023-12-20 2025-06-26 Perfuse Therapeutics, Inc. Methods of preparing drug delivery systems for the treatment of ocular diseases
AU2024405327A1 (en) * 2023-12-20 2026-07-02 Perfuse Therapeutics, Inc. Methods of preparing drug delivery systems for the treatment of ocular diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020082285A1 (en) * 2000-12-21 2002-06-27 Lebwohl David E. Method for preventing or treating pain by administering an endothelin antagonist
JP2009535422A (ja) * 2006-05-04 2009-10-01 アラーガン、インコーポレイテッド 血管作動薬を含有する持続放出性眼内インプラント
WO2020242264A1 (en) * 2019-05-31 2020-12-03 Samjin Pharmaceutical Co., Ltd. A composition for treating eye diseases

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4282793A (en) 1992-04-10 1993-11-18 State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University A microneedle for injection of ocular blood vessels
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
CZ20032350A3 (en) 2001-02-02 2004-03-17 Merck Patent Gmbh PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO 4,3-d PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS
US20030176356A1 (en) 2001-04-24 2003-09-18 University Of North Texas Health Science Center Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma
GB0122318D0 (en) 2001-09-14 2001-11-07 Novartis Ag Organic compounds
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
CA2697057A1 (en) 2007-08-22 2009-02-26 Gilead Colorado, Inc. Therapy for complications of diabetes
PL2424530T3 (pl) 2009-04-30 2016-07-29 Univ Midwestern Sposób i kompozycja do leczenia cukrzycowej kwasicy ketonowej
US20110082151A1 (en) 2009-06-12 2011-04-07 Auspex Pharmaceuticals, Inc. Sulfonylurea modulators of endothelin receptor
AR080888A1 (es) 2010-04-12 2012-05-16 R Tech Ueno Ltd Uso de un derivado de acido graso para producir una composicion oftalmica
EP2956096A1 (en) 2013-02-15 2015-12-23 Allergan, Inc. Sustained drug delivery implant
EP4046628A1 (en) 2013-10-31 2022-08-24 Allergan, Inc. Prostamide-containing intraocular implants and methods of use thereof
ES2813383T3 (es) 2013-12-19 2021-03-23 Tassos Georgiou Composición de ácidos grasos omega 3 para tratar enfermedades que implican daños en el sistema nervioso
ES2584534B1 (es) 2015-03-27 2017-03-13 Retinset, S.L. Formulación tópica oftálmica de bosentan
JP2018522942A (ja) * 2015-05-29 2018-08-16 エッジ セラピューティクス インコーポレイテッド 視力障害を低減するための組成物及び方法
CN115337254A (zh) 2015-07-23 2022-11-15 爱瑞制药公司 用于治疗眼病的玻璃体内药物递送系统
WO2017217967A1 (en) 2016-06-13 2017-12-21 Noveome Biotherapeutics, Inc. Novel methods for delivering therapeutic agents to the eye via nasal passages
WO2018185516A1 (en) 2017-04-05 2018-10-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
US11286274B2 (en) 2017-06-19 2022-03-29 Mitopower Llc Nicotinamide riboside derivatives and their uses
US10905770B2 (en) * 2017-07-17 2021-02-02 Macregen, Inc. Topical delivery of therapeutic agents using cell-penetrating peptides for the treatment of age-related macular degeneration and other eye diseases
WO2019210194A1 (en) 2018-04-26 2019-10-31 Vitrisa Therapeutics, Inc. Pegylated compositions for ocular use, and methods thereof
CA3132635A1 (en) 2019-03-05 2020-09-10 Aerie Pharmaceuticals, Inc. Pharmaceutical compositions for treating ocular diseases or disorders
JP7664239B2 (ja) * 2019-10-30 2025-04-17 パフューズ セラピューティクス, インコーポレイテッド エンドセリンレセプターアンタゴニストを使用する眼疾患の処置
CA3168810A1 (en) 2020-02-06 2021-08-12 Perfuse Therapeutics, Inc. Compositions for treatment of ocular diseases
CN117295520A (zh) * 2021-04-30 2023-12-26 珀弗斯治疗股份有限公司 使用内皮素受体拮抗剂治疗眼部疾病
BR112023022705A2 (pt) * 2021-04-30 2024-01-16 Perfuse Therapeutics Inc Composições farmacêuticas e sistemas de entrega intravítrea de fármacos para o tratamento de doenças oculares

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020082285A1 (en) * 2000-12-21 2002-06-27 Lebwohl David E. Method for preventing or treating pain by administering an endothelin antagonist
JP2009535422A (ja) * 2006-05-04 2009-10-01 アラーガン、インコーポレイテッド 血管作動薬を含有する持続放出性眼内インプラント
WO2020242264A1 (en) * 2019-05-31 2020-12-03 Samjin Pharmaceutical Co., Ltd. A composition for treating eye diseases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
NATESAN MURUGESAN ET AL.: ""Biphenylsulfonamide Endothelin Receptor Antagonists. 4. Discovery of N-[[2‘-[[(4,5-Dimethyl-3-isox", JOURNAL OF MEDICINAL CHEMISTRY, vol. 46, no. 1, JPN6026010199, 2003, pages 125 - 137, ISSN: 0005889141 *
SAEED F. ALRASHDI ET AL.: ""Intravitreal administration of endothelin type A receptor or endothelin type B receptor antagonists", EXPERIMENTAL EYE RESEARCH, vol. 176, JPN6026010198, 2018, pages 1 - 9, ISSN: 0005889143 *
中山和彦ら: ""エンドセリン受容体拮抗薬の臨床応用から今後の課題"", 心臓, vol. 45, no. 12, JPN6026025827, 2013, pages 1503 - 1511, ISSN: 0005889142 *

Also Published As

Publication number Publication date
BR112023022705A2 (pt) 2024-01-16
IL307997A (en) 2023-12-01
US20260130890A1 (en) 2026-05-14
MX2023012723A (es) 2024-02-08
KR20240004643A (ko) 2024-01-11
US11786510B2 (en) 2023-10-17
US20230105507A1 (en) 2023-04-06
US12622894B2 (en) 2026-05-12
CA3218251A1 (en) 2022-11-03
WO2022232588A1 (en) 2022-11-03
AU2022264036A1 (en) 2023-11-23
US20230414577A1 (en) 2023-12-28
EP4329753A1 (en) 2024-03-06
EP4329753A4 (en) 2025-02-26

Similar Documents

Publication Publication Date Title
US12622894B2 (en) Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases
JP7774170B2 (ja) 翼状片を治療するための組成物及び方法
KR20170094794A (ko) 수니티닙 제제 및 눈 장애의 치료에서의 그의 사용 방법
AU2019358200B2 (en) Macrocyclic lactone formulations, methods of their preparation and use of the formulations in treating pathologies secondary to ophthalmic parasites
KR101784260B1 (ko) 다형체 조성물, 이의 제조 방법 및 용도
EA032779B1 (ru) Фармацевтические композиции и соли 1,2,4-оксадиазолбензойной кислоты
JP2022554277A (ja) エンドセリンレセプターアンタゴニストを使用する眼疾患の処置
JP2017519813A (ja) 局所製剤およびその使用
KR20220143685A (ko) 안질환의 치료를 위한 조성물
TW202345803A (zh) 由投予眼部藥物遞送插入物預防老年黃斑部病變之方法
KR20240156416A (ko) 눈의 병태 치료를 위한 지속적 투여 요법
TW202222298A (zh) 含有可溶解的眼部插入物之藥物及其使用方法
US20070167526A1 (en) Topical mecamylamine formulations for ocular administration and uses thereof
US20240058265A1 (en) Treatment of ocular diseases using endothelin receptor antagonists
CN117580574A (zh) 用于治疗眼病的药物组合物和玻璃体内药物递送系统
WO2025137005A1 (en) Methods of preparing drug delivery systems for the treatment of ocular diseases
WO2025137007A1 (en) Methods of preparing drug delivery systems for the treatment of ocular diseases
HK40069641A (en) Compositions and methods for treating pterygium
EA044938B1 (ru) Композиции для лечения болезней глаз
MX2008008016A (en) Topical mecamylamine formulations for ocular administration and uses therof
HK1256602B (en) Compositions and methods for treating pterygium

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250430

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250430

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260619